Research and Markets (http://www.researchandmarkets.com/research/26fb40/commercial_insight) has announced the addition of the "Commercial Insight: Antidiabetics in Australia - Reimbursement Status Shapes Novel Classes" report to their offering.
Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now.
Scope
- Forecast for marketed and late-stage pipeline antidiabetic products in Australia
- Assessment of Australia-specific drivers and resistors likely to impact the market
- Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates
- Case study examining the approval and reimbursement process in Australia in general and for several antidiabetics in specific
Highlights of this title: